Antifibrinolytics.
Schmarts
D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology*; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D014148:Tranexamic Acid; D007611:Aprotinin; D015119:Aminocaproic Acid